AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study

MT Newswires Live

02-26

AIM ImmunoTech (AIM) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's (AZN) Imfinzi as a potential combination to treat late-stage pancreatic cancer.

Phase 2 will also include various subjects who received the highest dose, AIM said.

The company said that up to 25 patients are expected to be enrolled in the study's phase 2.

AIM shares were down over 8% in recent trading.

Price: 0.12, Change: -0.01, Percent Change: -8.44

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514019457"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514019457\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514019457?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-26 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514019457","market":"hk","top_or_hot":-1,"title":"AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study","media":"MT Newswires Live","content":"<html><body><p> AIM ImmunoTech (AIM) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's (AZN) Imfinzi as a potential combination to treat late-stage pancreatic cancer.</p><p>Phase 2 will also include various subjects who received the highest dose, AIM said.</p><p>The company said that up to 25 patients are expected to be enrolled in the study's phase 2.</p><p>AIM shares were down over 8% in recent trading.</p><p>Price: 0.12, Change: -0.01, Percent Change: -8.44</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-26 00:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> AIM ImmunoTech (AIM) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's (AZN) Imfinzi as a potential combination to treat late-stage pancreatic cancer.</p><p>Phase 2 will also include various subjects who received the highest dose, AIM said.</p><p>The company said that up to 25 patients are expected to be enrolled in the study's phase 2.</p><p>AIM shares were down over 8% in recent trading.</p><p>Price: 0.12, Change: -0.01, Percent Change: -8.44</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514019457","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514019457","pubTimestamp":1740500089,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"AIM ImmunoTech  said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's  Imfinzi as a potential combination to treat late-stage pancreatic cancer.Phase 2 will also include various subjects who received the highest dose, AIM said.The company said that up to 25 patients are expected to be enrolled in the study's phase 2.AIM shares were down over 8% in recent trading.Price: 0.12, Change: -0.01, Percent Change: -8.44","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"AIM ImmunoTech为晚期胰腺癌研究2期首例受试者给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM":1,"AIM.AU":1,"AZN":0.9,"SSI":1},"content_text":"AIM ImmunoTech (AIM) said Tuesday it has dosed the first new subject in phase 2 of a phase 1b/2 clinical trial evaluating the company's Ampligen and AstraZeneca's (AZN) Imfinzi as a potential combination to treat late-stage pancreatic cancer.Phase 2 will also include various subjects who received the highest dose, AIM said.The company said that up to 25 patients are expected to be enrolled in the study's phase 2.AIM shares were down over 8% in recent trading.Price: 0.12, Change: -0.01, Percent Change: -8.44","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}